Acute and 28-day subchronic toxicity studies of mangiferin, a glucosyl xanthone isolated from Mangifera indica L. stem bark

[Toxicidad aguda y subcrónica (28 días) de la mangiferina, una glucosil xantona aislada de la corteza de Mangifera indica L.]

Yalena Prado1, Nelson Merino2, Jhoany Acosta1, José A. Herrera3, Yilian Luque4, Ivones Hernández5, Elisa Prado1, Gabino Garrido5, René Delgado2, Idania Rodeiro5*

1Departamento de Bioingeniería, Facultad de Ingeniería Eléctrica, Universidad Politécnica José Antonio Echeverría, Marianao, e/ 114 y Ciclovía; 2Laboratorio de Farmacología, Centro para la Investigación y Desarrollo de Medicamentos, 26 y 51, Plaza de la Revolución, 10400; 3División de Nanomateriales, Instituto de Ciencia y Tecnología de Materiales (IMRE), Universidad de La Habana, Zapata y G, Vedado; 4Departamento de Inmunología, Centro de Química Biomolecular, 200 y 21, Atabey, Playa; 5Departamento de Farmacología, Centro de Bioproductos Marinos (CEBIMAR), Loma 37, Vedado, 10400, La Habana, Cuba.

Abstract

Context: Pharmacological properties of mangiferin have been reported, but few studies have investigated mangiferin toxicity.

Aims: To study the acute and 28-day toxicity effects of mangiferin in rodents.

Methods: Single doses of mangiferin were administered by oral or i.p. route or were applied dermally to Sprague-Dawley rats and Balb/C mice. Clinical symptoms of animals were observed during 14 days after treatment. Animals also received single oral doses daily for 28 consecutive days. Blood biochemistry, hematological and pathological findings were reported.

Results: In the acute study, no toxic effects were observed after dermal exposure to mangiferin 2000 mg/kg but transient dyspnea, flank position and piloerection were observed after oral administration to this xanthone. I.p. administration induced similar toxicity signs, but at the highest dose (2000 mg/kg) all mice, one female rat and one male rat died. Rats orally treated with mangiferin (250-1000 mg/kg) for 28 days did not show any abnormal clinical signs or hematological alterations, when compared to control group animals. Histopathological alterations like vacuolar degeneration, necrosis and increment of apoptosis of the acinar cells were observed in the exocrine pancreas of rats at 1000 mg/kg. This suggesting that exocrine pancreas was the target organ for mangiferin’s toxicity.

Conclusions: These studies indicated that acute and subchronic toxicities of mangiferin for oral exposure are low.

Keywords: Acute dose; mangiferin; repetitive toxicity assay; toxicological studies; xanthone.

Keywords: Toxicidad aguda y subcrónica de mangiferina; ensayo de dosis repetidas; estudios toxicológicos; mangiferina; xantona.
INTRODUCTION

Polyphenols are a large group of natural compounds that include flavonoids, anthocyanins and tannins, among others. They are widely distributed in food sources, and they are ingested daily in significant quantities as part of the diet. Potent antioxidant effects have been reported for these molecules, which depend on their free-radical scavenging capacity and iron-chelating activity, among other biological properties (Paulettil et al., 2003; Wu et al., 2008; Nuñez et al., 2009). They are also the broad source of antioxidants consumed by humans and are promising candidates to explain the protective effects of fruit and vegetables against oxidative damage related diseases like coronary heart diseases, stroke, and cancer. Other properties have also been attributed to natural polyphenols: antiviral, antibacterial, anti-inflammatory, neuroprotective and antitumor action, as well as the ability to modulate certain signalling pathways like nuclear factor-kappa B activation (Aggarwal and Shishodia, 2006; Chen and Dou, 2008; Campos et al., 2009; Darvesh et al., 2010; Noratto et al., 2010). In short, plant polyphenols are a versatile group of chemical entities with many potential human benefits like phytomedicines that raise the necessity for increasing available data about their risk-benefit margin.

Mangiferin is a glucosyl xanthone widely distributed in higher plants, i.e. Anacardiaceae and Gentianaceae families, and recently it has attracted the attention of many researchers in different parts of the world. Several properties have been reported for mangiferin, for instance: anti-oxidant, anti-diabetic, anti-cancer, immunomodulatory, anti-genotoxic and anti-inflammatory (Muruganandan et al., 2005; Garrido et al., 2004; 2007; Leiro et al., 2004; Dar et al., 2005; Amazzal et al., 2007; Rajendran et al., 2008; Lee et al., 2009; Prabhu et al., 2009; Satish et al., 2009; Li et al., 2010; Viswanadh et al., 2010). Some studies have been performed in Cuba with isolated and purified mangiferin from one standardized aqueous stem bark of Mangifera indica L. tree (mango) extract (MSBE). They support the potential therapeutic uses of mangiferin in diseases where oxidative stress and inflammation are highly present (Sanchez et al., 2000; Garrido et al., 2004; Rodeiro et al., 2008; 2014; Garcia et al., 2011; Garrido-Suarez et al., 2014; Rodriguez et al., 2014; Tolosa et al., 2014).

However, few studies have been performed for describing the potential toxicological effects of this compound. Jagetia and Baliga (2005) reported that intraperitoneal (i.p.) LD\textsubscript{50} of mangiferin in DBAxC57BL mice was 400 mg/kg. Govindraj et al. (2009) showed that the mangiferin was not mutagenic to Salmonella typhimurium strains by using the Ames assay. Studies performed by us showed mangiferin is non-cytotoxic and non-genotoxic in a battery of assays (Rodeiro et al., 2012). Previous studies were performed to evaluate the toxicity effects of MSBE, where mangiferin is the principal component (Garrido et al., 2009). They show that the LD\textsubscript{50} of MSBE administered to rats and mice by oral route is higher than 5000 mg/kg, reporting only some transient toxicity signs like dyspnoea, flank position and piloerection as well as reduced locomotion activity in the animals exposed to the extract. Similar toxicity signs are observed when MSBE is administered to animals by i.p. route, but under these conditions the extract is considered toxic according to the Acute Toxic protocols. MSBE is not toxic to Sprague-Dawley rats after a 90-day exposure to oral doses up to 1 000 mg/kg.

Expectations around the possible beneficial use of mangiferin in humans as a new medicinal drug make necessary the toxicological characterization of this natural product. To accomplish this purpose, we carried out oral acute, dermal and i.p. toxicity assays in rats and mice and a 28 day-long repetitive doses study of mangiferin in rats.

MATERIAL AND METHODS

Materials

The batch of mangiferin (No. 010) used in the study was supplied by the Laboratory of Chemistry for Natural Products at the Drug Research and Development Center of Cuba (CIDEM, Havana, Cuba) and was assessed with a validated HPLC-based method (Nuñez et al., 2002). Mangiferin (1,3,6,7-tetrahydroxy xanthone-C2-β-
d-glucoside) was purified from the MSBE by extraction with methanol according to the standard method as described (Nuñez et al., 2002); purity was 92%.

**Animals**

Rats and mice were obtained from the Centro para la Producción de Animales de Laboratorio (CENPALAB, Havana, Cuba) and were acclimatized to the environmental conditions for one week before tests. Male and Female Sprague-Dawley rats weighing 150-200 g and Balb/C mice of both sexes weighing 20-25 g were used in an acute toxicity assay. Male and female rats used in a repetitive dose toxicity assay were six weeks old at the onset of dosing. Animals were housed in plastic and stainless-steel grid-floored cages, which were kept at 23 ± 2°C, relative humidity 40-60%, 12 h light/dark cycles with food and water ad libitum. The mice and rats employed were randomly distributed for tests. In the acute toxicity studies, 3 animals/sex/doses were used, and for the repetitive dose assay 12 animals/sex/groups were randomly assigned to 4 groups (control, low, medium and high dose groups).

**Experimental designs**

All studies were in compliance with Good Laboratory Practice (GLP) standards. The experiments were conducted in accordance with the ethical guidelines for investigations in laboratory animals and were approved by the Ethical Committee for Animal Experimentation of the Drug Research and Development Center (CIDEM), La Habana, Cuba.

**Acute oral toxicity study**

A single dose level of mangiferin at 2 000 mg/kg per body weight was administered via gastric intubation to mice and rats according to the ATC method described in the OECD Protocol 423 (2000). Mangiferin was suspended in carboxymethyl cellulose (CMC) 0.5% and administered at 10 mL/kg to mice and 5 mL/kg to rats.

**Acute dermal toxicity study**

A volume of 0.1 mL of mangiferin was administered dermally to the dorsal region of each animal (as a single dose of 2 000 mg/kg per body weight in a shaved area), representing the 10% of the total body surface area, according to OECD Protocol 434 (2004).

**Acute i.p. toxicity study**

The doses for mice and rats were selected according to the Acute Toxicity Class (ATC) method (OECD, 2000). The first dose of mangiferin was 2000 mg/kg per body weight following a second one of 300 mg/kg per body weight dissolved in Tween 20 (0.4% in distilled water).

**Observations of clinical signs**

Animals were closely observed during the first 24 h post-administration for detecting clinical signs that included morbidity and mortality. The time of appearance, duration and intensity of every clinical sign were also recorded. Animals were also observed for the remaining 14 days in order to detect and record changes in appearance, overt behaviour, skin, fur, eyes, and mucous membranes, as well as any disturbances in respiration, autonomic or central nervous system. Body weight data were recorded at the beginning and the end of the study. The incidence of gross pathological changes was also observed during the necropsy performed at day 14 in each study.

**Repetitive dose oral toxicity study**

The test material was administered by single oral intubations during 28 consecutive days. Four experimental groups (12 animals/sex/groups) were included: three groups were treated with mangiferin at doses of 250, 500 and 1000 mg/kg and the control group received equivalent volumes of CMC (0.5%). During the administration period, animal general appearance was measured weekly and at necropsy.

At the end of the study, animals were fasted for 16–19 h and on the necropsy day they were anesthetized with diethyl ether. Blood samples...
were collected from the abdominal aorta and around 1 mL of blood was treated with EDTA for determining hematocrit (Ht), haemoglobin concentration (Hb), differential percentage of total leukocytes (lymphocytes, monocytes, eosinophils), erythrocytes and platelet count. Analyzes were performed by using a Haematology analyzer F-850 (Sysmex Co., LTD). The differential white blood count was measured by using the Brecher method and the May-Grunwald-Giemsa staining method. Serum from blood samples were collected and the following parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose, total cholesterol, triglyceride, uric acid, creatinine (CR) and albumin concentration were measured by means of a 7150 automatic analyzer (Hitachi Co., Ltd.).

Pathological examination

During necropsy, the abdominal, thoracic and cranial cavities of each animal were examined while the liver, spleen, heart, kidneys, lungs, thymus and brain were weighed (Sartorius Universal Scale, Goettingen, Germany). Tissue samples were taken from all animals in the study: Samples came from the above mentioned organs and from lymph nodes, bone red marrow, pituitary gland, thyroid with parathyroid, larynx/trachea, bronchi, salivary glands, tongue, oesophagus, stomach, small and large intestines, pancreas, penis, urinary bladder, vagina, skeletal muscle, skin, eyes, Harderian glands, Zymbal gland, sciatic nerve, cerebrum, cerebellum and spinal cord. Samples were preserved in 10% buffered formaldehyde, embedded in paraffin, sectioned with a rotary microtome (Leitz microtome, Wetzlar, Germany), stained with hematoxylin and eosin and examined by light microscopy. An Olympus BH2 microscope (Olympus Optical Co., Ltd. Tokyo, Japan) was used for these observations.

Statistical analysis

Means and standard deviations of body weight, food consumption, haematology, blood chemistry and relative organ weights were determined. One-way breakdown ANOVA followed by the Dunnett multiple comparison tests were used in order to compare each group with controls. Relative organ weight data was transformed as arcsin(√datum) to achieve normality. Homoscedasticity was assessed by the Bartlett test for homogeneity of variances. In the absence of variance homogeneity, the Kruskal-Wallis test was used. Statistical significance level was p < 0.05.

RESULTS

Oral acute studies of mangiferin in rodents

All animals survived the 14-day observation period after oral administration of 2000 mg/kg of mangiferin, and their body weight increased during this time. Only transitory piloerection and decrease in the motor activity were observed during the first three hours after administration. It was not found gross pathology alterations at necropsy, and no significant changes were observed in any organ (data not shown).

Dermal acute studies of mangiferin in rodents

No toxic effects were observed in mice and rats after dermal exposure to 2000 mg/kg mangiferin doses. No were detected deaths neither clinical findings related to mangiferin nor remarkable body weight changes nor other local reaction associated with treatment.

Intraperitoneal acute studies of mangiferin in rodents

Some animals died in the i.p. acute toxicity assays within 72 h of treatment. All mice administered with the highest dose level (2000 mg/kg) died, but rats tolerated better than mice with mortality only in one male and one female animal. However, no mice or rats died at the 300 mg/kg dose level groups. Signs observed in animals (rats and mice) prior to death were: decreased motor activity, decreased response to the stimulus, prostration, piloerection, ataxia and dyspnea. The animal that survived showed just piloerection during the whole period of the
experiment. No significant changes were detected at necropsy in any organs from the animals that survived.

**Repetitive doses oral toxicity study of mangiferin in rats**

No animals died during the 28 day-long oral toxicity study of mangiferin in rats. In the 250 and 500 mg/kg groups, there were no abnormal findings in males or females. Only few toxicity signs were observed during the study in the animals treated with the highest dose of mangiferin (1000 mg/kg). Two female rats showed the following toxicity signs, after day 21: decreased motor activity, decreased response to the stimulus, prostration, piloerection and ataxia, all signs were kept until sacrifice on day 28. Three male rats showed piloerection, which coincidently was the most persistent finding observed in the acute study. There were no significant differences (p > 0.05) in body weight between groups during the administration period (Fig. 1). Body weight gain and food consumption were unaffected by mangiferin exposure during the trial.

No significant differences were observed (p > 0.05) in the haematological and clinical chemistry parameters in female and male rats (Tables 1 and 2). These parameters were within normal range according to physiological background data, and the historical values reported for these animals (Alemán et al., 1998).

The results of the absolute weight of organs are shown in Table 3. Gross necropsy findings did not reveal changes in any organs and tissues examined. There were no statistically significant differences between the control group and the mangiferin-treated groups in organ weight. Recorded values were also within the normal physiological range described for this species. A search for histopathological changes was also carried out to the organs and tissues of controls and animals treated with the different dose levels of mangiferin. As it can be observed (Table 4), the exocrine pancreas was the unique target organ for mangiferin toxicity. The main findings observed were: vacuolar degeneration, basophilic cytoplasm changes, necrosis and apoptosis of the acinar cells, which was explained as diffuse non-inflammatory exocrine pancreas atrophy. No other inflammatory reaction was found (Fig. 2).

---

**Figure 1.** Body weight of female (A) and male (B) rats during the study of repetitive oral dose toxicity. Control groups are represented by solid gray bars while doses of mangiferin were 250 mg/kg (light gray stripes), 500 mg/kg (black dotted), and 1000 mg/kg (solid black). Data are presented as mean ± SD. No significant differences were observed between groups, Dunnett’s Test, p > 0.05.
Table 1. Blood biochemical parameters in rats after 28 days of mangiferin oral administration.

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Glucose (g/L)</th>
<th>Creatinine (mmol/L)</th>
<th>ALT (U/L)</th>
<th>AST (U/L)</th>
<th>Cholesterol (mmol/L)</th>
<th>Triglycerides (mmol/L)</th>
<th>Uric acid (mmol/L)</th>
<th>Albumin (g/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5.2 ± 2.0</td>
<td>45.3 ± 13.0</td>
<td>42.7 ± 9.7</td>
<td>247.0 ± 51.0</td>
<td>0.47 ± 0.2</td>
<td>0.78 ± 0.1</td>
<td>95.1 ± 24.6</td>
<td>36.7 ± 3.4</td>
</tr>
<tr>
<td>250</td>
<td>4.4 ± 1.3</td>
<td>51.3 ± 15.9</td>
<td>47.9 ± 9.3</td>
<td>297.8 ± 54.2</td>
<td>0.84 ± 0.3</td>
<td>0.82 ± 0.2</td>
<td>150.4 ± 38.3</td>
<td>40.3 ± 2.6</td>
</tr>
<tr>
<td>500</td>
<td>4.5 ± 1.2</td>
<td>56.0 ± 14.0</td>
<td>51.3 ± 16.5</td>
<td>279.1 ± 66.1</td>
<td>0.49 ± 0.4</td>
<td>0.95 ± 0.3</td>
<td>146.6 ± 95.1</td>
<td>39.6 ± 3.8</td>
</tr>
<tr>
<td>1000</td>
<td>4.5 ± 0.9</td>
<td>49.9 ± 11.3</td>
<td>53.6 ± 16.0</td>
<td>284.1 ± 49.7</td>
<td>0.55 ± 0.3</td>
<td>0.78 ± 0.1</td>
<td>138.2 ± 64.2</td>
<td>39.0 ± 2.1</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD. Each group included 12 animals. No significant differences were observed among groups, Dunnett’s Test, p > 0.05.

Table 2. Haematological parameters in rats after 28 days of mangiferin oral administration.

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Platelets (x10⁹/L)</th>
<th>Leucocytes (x10⁹/L)</th>
<th>Lymphocytes (%)</th>
<th>Monocytes (%)</th>
<th>Eosinophils (%)</th>
<th>Hematocrit (%)</th>
<th>Hemoglobin (g/dl)</th>
<th>Erythrocytes (x10⁶/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>313.3 ± 89.6</td>
<td>9.1 ± 2.5</td>
<td>79.6 ± 2.3</td>
<td>2.1 ± 1.0</td>
<td>1.5 ± 1.2</td>
<td>44.4 ± 1.5</td>
<td>14.7 ± 0.6</td>
<td>8.0 ± 0.5</td>
</tr>
<tr>
<td>250</td>
<td>350.8 ± 76.2</td>
<td>8.5 ± 2.2</td>
<td>82.1 ± 2.4</td>
<td>2.9 ± 1.0</td>
<td>1.1 ± 1.3</td>
<td>45.2 ± 1.7</td>
<td>14.4 ± 0.9</td>
<td>7.7 ± 0.5</td>
</tr>
<tr>
<td>500</td>
<td>361.7 ± 51.2</td>
<td>9.8 ± 1.5</td>
<td>81.3 ± 2.6</td>
<td>2.2 ± 1.8</td>
<td>1.0 ± 1.3</td>
<td>44.2 ± 1.8</td>
<td>14.4 ± 0.8</td>
<td>7.6 ± 0.4</td>
</tr>
<tr>
<td>1000</td>
<td>319.5 ± 85.7</td>
<td>8.7 ± 3.0</td>
<td>80.8 ± 1.4</td>
<td>1.5 ± 0.9</td>
<td>2.0 ± 1.9</td>
<td>46.6 ± 4.5</td>
<td>14.8 ± 1.0</td>
<td>7.9 ± 0.3</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD. Each group included 12 animals. No significant differences were observed among groups, Dunnett’s Test, p > 0.05.
Table 3. Relative organ weight in rats after 28 days of mangiferin oral administration.

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Heart (%)</th>
<th>Liver (%)</th>
<th>Lungs (%)</th>
<th>Kidneys (%)</th>
<th>Spleen (%)</th>
<th>Thymus (%)</th>
<th>Brain (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.39 ± 0.08</td>
<td>3.02 ± 0.52</td>
<td>0.60 ± 0.12</td>
<td>0.88 ± 0.20</td>
<td>0.24 ± 0.04</td>
<td>0.24 ± 0.08</td>
<td>0.52 ± 0.12</td>
</tr>
<tr>
<td>250</td>
<td>0.38 ± 0.04</td>
<td>3.07 ± 0.25</td>
<td>0.63 ± 0.08</td>
<td>0.80 ± 0.17</td>
<td>0.25 ± 0.04</td>
<td>0.25 ± 0.04</td>
<td>0.63 ± 0.08</td>
</tr>
<tr>
<td>500</td>
<td>0.36 ± 0.04</td>
<td>2.89 ± 0.24</td>
<td>0.59 ± 0.12</td>
<td>0.72 ± 0.08</td>
<td>0.24 ± 0.04</td>
<td>0.24 ± 0.08</td>
<td>0.55 ± 0.12</td>
</tr>
<tr>
<td>1000</td>
<td>0.42 ± 0.13</td>
<td>3.42 ± 0.42</td>
<td>0.68 ± 0.13</td>
<td>0.97 ± 0.30</td>
<td>0.25 ± 0.04</td>
<td>0.21 ± 0.04</td>
<td>0.55 ± 0.04</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.37 ± 0.09</td>
<td>2.77 ± 0.58</td>
<td>0.43 ± 0.06</td>
<td>0.78 ± 0.14</td>
<td>0.18 ± 0.03</td>
<td>0.18 ± 0.06</td>
<td>0.43 ± 0.06</td>
</tr>
<tr>
<td>250</td>
<td>0.35 ± 0.09</td>
<td>2.71 ± 0.59</td>
<td>0.47 ± 0.09</td>
<td>0.74 ± 0.18</td>
<td>0.19 ± 0.03</td>
<td>0.15 ± 0.03</td>
<td>0.38 ± 0.18</td>
</tr>
<tr>
<td>500</td>
<td>0.38 ± 0.06</td>
<td>2.91 ± 0.44</td>
<td>0.50 ± 0.12</td>
<td>0.82 ± 0.12</td>
<td>0.20 ± 0.03</td>
<td>0.17 ± 0.03</td>
<td>0.44 ± 0.06</td>
</tr>
<tr>
<td>1000</td>
<td>0.38 ± 0.11</td>
<td>2.66 ± 0.54</td>
<td>0.49 ± 0.08</td>
<td>0.76 ± 0.16</td>
<td>0.22 ± 0.05</td>
<td>0.19 ± 0.05</td>
<td>0.38 ± 0.05</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD. All groups included 12 animals. % represent the relative weight of organs respect to body weight (100%). No significant differences were observed between groups, Dunnett’s Test, p > 0.05.

Table 4. Non-neoplastic histopathological lesions found in the pancreas after 28 days oral administration of mangiferin to Sprague-Dawley rats.

<table>
<thead>
<tr>
<th>Observations</th>
<th>Control</th>
<th>Mangiferin (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>250</td>
</tr>
<tr>
<td></td>
<td></td>
<td>500</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apoptosis of the acinar cells</td>
<td>o/12</td>
<td>2/12</td>
</tr>
<tr>
<td>Cell mitosis (Metaphase)</td>
<td>o/12</td>
<td>1/12</td>
</tr>
<tr>
<td>Acinar cell necrosis (without inflammation)</td>
<td>o/12</td>
<td>0/12</td>
</tr>
<tr>
<td>Cluster of basophilic acinar cells with loss of the Zymogen granules</td>
<td>o/12</td>
<td>o/12</td>
</tr>
<tr>
<td>Vacuolar degeneration</td>
<td>o/12</td>
<td>o/12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apoptosis of the acinar cells</td>
<td>o/12</td>
<td>2/12</td>
</tr>
<tr>
<td>Acinar cell necrosis (without inflammation)</td>
<td>o/12</td>
<td>0/12</td>
</tr>
<tr>
<td>Cluster of basophilic acinar cells with loss of the Zymogen granules</td>
<td>o/12</td>
<td>o/12</td>
</tr>
<tr>
<td>Vacuolar degeneration</td>
<td>o/12</td>
<td>0/12</td>
</tr>
</tbody>
</table>

http://jppres.com/jppres

Figure 2. Photomicrograph showing pancreas from a representative animal of the doses of 1000 mg/kg with lesions in exocrine pancreatic acinar cells. (A) Exocrine pancreas with increased basophilia. (B) Cell apoptosis. (C) Acinar cell necrosis and loss of zymogen granules. (D) Vacuolar degeneration and loss of zymogen granules.

DISCUSSION

There are an increased number of recent reports regarding that polyphenols derived from plant sources may have the capacity to modulate the pathology of chronic diseases like cancer, diabetes, neurodegenerative disorders, cardiovascular disease and inflammatory and infectious processes (Aggarwal et al., 2006; Chen and Dou, 2008; Campos et al., 2009; Darvesh et al., 2010; Noratto et al., 2010). Therefore, many researchers are currently in the search of medicinal plants for extracting components thereof in order to support the cure of these pathologies. However, all those possible candidates require medicinal health guarantees provided by the toxicological studies and an analysis of the action mechanisms. The toxicology studies with mangiferin described in this report provided the first tests to establish the safety of this product.

Exposure of Sprague-Dawley rats and Balb/C mice to oral and dermal single dose of mangiferin did not produce any treatment-related effect. The consequence of mangiferin exposure to 2000 mg/kg body weight in i.p. single dose by sex caused death in the animals. However, in another
study LD₅₀ value reported for mangiferin was 400 mg/kg after acute i.p. administration to DBAxC57BL mice (Jagetia and Baliga, 2005). We have previously reported that the mangiferin is neither cytotoxic nor mutagenic nor genotoxic in several in vivo and in vitro assays (Rodeiro et al., 2012). Similar results are reported for MSBE applied to Balb/C mice and Sprague-Dawley rats from both sexes in an acute toxicity assay (Garrido et al., 2009). MSBE is extracted from the mango tree; it is rich in polyphenols structures where mangiferin represents almost 20% of the polyphenol total (Nuñez et al., 2002). Thus, our present data agreed with the acute toxicological potential reported by these authors. Body weight and food consumption of the animals that survived regularly increased in accordance with the published values for the species (Alemán et al., 1998).

The exposure of male and female rats to 1000 mg/kg doses of mangiferin induced significant damage to the acinar cells of the exocrine pancreas at the repetitive doses assay. We explained this as diffuse non-inflammatory exocrine pancreas atrophy. The absence of inflammatory reaction in cases of induced exocrine pancreas atrophy was probably related to alterations in protein synthesis (Greaves and Faccini, 1984; Smith et al., 1982). Repeated doses of cyclosporine produce similar damage to the exocrine pancreas (Hiirakawua et al., 1991). These authors suggest that prolonged treatments with cyclosporine may induce suppression of the exocrine pancreas function, probably because of the inhibition of DNA and protein synthesis. Therefore, the potential effects of mangiferin over protein synthesis should not be overlooked. Other authors have reported in vitro and in vivo anti-diabetic activity for mangiferin (Muruganandan et al., 2005; Li et al., 2010; Lin et al., 2010), which indicates that the pancreas is a pharmacological target for this molecule. However, the toxic signs were observed only at the highest dose levels of mangiferin (1000 mg/kg). Such toxic signs might be related to exacerbation of the pharmacological mechanism of mangiferin under these experimental conditions rather than an intrinsic cytotoxic effect. Accordingly, in order to corroborate this hypothesis, other studies should be performed.

CONCLUSIONS

In summary, we have demonstrated a low level of toxicity for orally administered mangiferin to rodents in acute and sub-chronic studies. Although some toxicity signs were observed in the repetitive dose assay, a wide safe margin is expected for orally administered mangiferin under our experimental conditions. A balance between therapeutic and toxicological effects of a new compound is an important parameter when verifying its applicability as a pharmacological drug. In our knowledge, the present study is the first battery of studies performed to investigate the mangiferin safety margin, a natural product under preclinical investigation as a candidate to a new phytotherapy.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENT

This work was partially supported by the projects PNAP-CIDEM 613007 (Cuba), VLIR-OUS 2011-062 (Belgium) and FONDECYT 1130601 (Chile).

REFERENCES


Mangiferin toxicity studies


http://jppres.com/jppres

http://jppres.com/jppres